Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth

British Journal of Cancer

Volumn 85, Issue 12, 2001, Pages 2010-2016

  Hess, C ^a   Vuong, V ^a   Hegyi, I ^a   Riesterer, O ^a   Wood, J ^b   Fabbro, D ^b   Glanzmann, C ^a   Bodis, S ^a   Pruschy, M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiogenesis; Radiosensitization; Tumour growth control; VEGF dependent proliferation

Indexed keywords

PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB;

ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; MICROVASCULATURE; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; UMBILICAL VEIN;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL DIVISION; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PHTHALAZINES; PROTEIN-TYROSINE KINASES; PYRIDINES; RADIOTHERAPY, ADJUVANT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035555907     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2166     Document Type: Article

References (33)

1. Inhibition of tumour growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor-121
2. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody; novel concepts of angiostatic therapy from intravital videomicroscopy
3. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
4. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
5. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis
6. Effects of PTK787/ZK222584/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumour, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
7. Angiogenesis in cancer, vascular, rheumatoid and other disease
8. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumour vascularization, and growth of multiple tumour types
9. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumour resistance to radiotherapy
10. Paracrine expression of an native soluble vascular endothelial growth factor receptor inhibits tumour growth, metastasis, and mortality rate
11. Potentiation of the antitumor effect of ionising radiation by brief concomitant exposures to angiostatin
12. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionising radiation
13. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
14. Vascular endothelial growth factors VEGF-B and VEGF-C
15. Anti-tumour and anti-metastatic effect of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplantation orthotopically into nude mice
16. Inhibition of vascular endothelial growth-factor-induced angiogenesis suppresses tumour growth in vivo
17. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumour xenografts
18. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells
19. Therapeutic synergy of TNP-40 and ionising radiation: Effects on tumour growth, vessel morphology and angiogenesis in human glioblastoma multiforme xenografts
20. Combined effects of angiostatin and ionising radiation in antitumour therapy
21. Vascular endothelial growth factor B, a novel growth factor for endothelial cells
22. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells
23. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
24. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family
25. Role of VEGF-flt receptor system in normal and tumour angiogenesis
26. (E)-2′-Deoxy-2′-(fluoromethylene) Cytidine potentiates radioresponse of two human solid tumour xenografts
27. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts
28. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma
29. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
30. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia 2nd edn
31. PTK787/ZK222584/ZK 222584 a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumour growth after oral administration
32. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D
33. Differential, p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412